Earnings, deals and disclosures from Japan's listed pharma & healthcare companies, in English.
Shionogi drew an unsecured ¥300bn bridge loan from Sumitomo Mitsui Banking Corporation on 10 November to fund its IntraBio purchase, and plans to refinance it into longer-term funding before the 29 October 2027 repayment date.
Nxera Pharma has withdrawn its 10% cap on share-based pay and will grant three executive officers options over up to 6.65mn shares, about 7.2% of shares outstanding, which vest only if price hurdles from ¥2,200 to ¥10,000 are met.
GNI Group says it will be added to TOPIX from October 30, selected from the Tokyo Stock Exchange's Growth market in the first regular reshuffle since the index opened selection to all three market segments.
A fund run by JIC Venture Growth Investments bought 619,700 Cuorips shares at ¥4,841 each in a third-party allotment, paid from its own fund money, and says it is a pure investment with no significant proposals.
The Cayman fund acquired warrants priced at ¥0.14 apiece that the filing logs under a 41.14% holding-ratio entry, then exercised and sold into the market through August, trimming its combined stake to 33.39% from 41.97% by September 1.
SymBio Pharmaceuticals lined up an estimated ¥6.77bn from Cayman fund EVO Fund to keep its antiviral drug trials funded through March 2028, but the bond-and-warrant structure could swell its share count by more than 125% if every warrant is exercised.
The Tokyo Growth-listed company delivered 906,000 new shares in the first month of a June 5 warrant issue, while rights linked to 13,876,000 shares remained unexercised at month-end.
Shareholders approved NPT's TOKYO PRO Market delisting application, putting July 29 as the last planned trading day before depository handling ends and brokers stop accepting related requests after delisting.
The June 26 appointment took effect immediately and leaves Sugii running the Prescription Kampo Medicine Company, with Tsumura saying it wants a stronger management structure and faster decisions.
BrightPath Bio says Tokuhiro Nakamura stepped down on June 25 for personal reasons, and that the departure does not take it below the director numbers required by law and its articles of incorporation.
The US registration covers Gyre shares issued in the Cullgen buyout, not fresh fundraising, and parent GNI says its effective interest stands at about 70 per cent with no material effect expected on consolidated results.
The 29th option series can be exercised only if Helios wins domestic approval for HLCM051 in ARDS and records at least ¥1.5bn of revenue in any year through 2032. Full exercise would equal 9.0% of shares outstanding, while the same-day 28th, 29th and 30th series together reach 14.0% dilution.
The structure: Modalis says the package can raise ¥1.33 billion, but only up to ¥300 million arrives upfront via a 0% private bond. The rest depends on EVO FUND exercising 24 million shares' worth of warrants at prices that reset to the previous day's close, with a ¥28 floor and disclosed maximum dilution of 24.91%.